Kelly Lawrence W & Associates Inc. CA maintained its stake in Sanofi (NYSE:SNY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,025 shares of the company’s stock at the end of the second quarter. Kelly Lawrence W & Associates Inc. CA’s holdings in Sanofi were worth $192,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in SNY. Guggenheim Capital LLC raised its stake in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the last quarter. Goodwin Daniel L acquired a new stake in shares of Sanofi during the second quarter valued at approximately $239,000. Wellington Management Group LLP acquired a new stake in shares of Sanofi during the first quarter valued at approximately $2,252,000. Cullinan Associates Inc. raised its stake in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in shares of Sanofi by 8.6% in the first quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares during the last quarter. Hedge funds and other institutional investors own 9.90% of the company’s stock.
Shares of Sanofi (SNY) traded up 0.23% during trading on Friday, reaching $48.19. The company’s stock had a trading volume of 573,279 shares. The company has a market capitalization of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88. The firm’s 50-day moving average price is $47.84 and its 200-day moving average price is $46.41. Sanofi has a one year low of $36.81 and a one year high of $50.24.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. Sanofi’s revenue was down 2.3% compared to the same quarter last year. On average, equities analysts anticipate that Sanofi will post $3.26 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Kelly Lawrence W & Associates Inc. CA Maintains Position in Sanofi (NYSE:SNY)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/19/sanofi-nysesny-stake-maintained-by-kelly-lawrence-w-associates-inc-ca-updated.html.
Several equities research analysts recently commented on the company. Argus upped their target price on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, June 9th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $54.00.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.